Citation Impact
Citing Papers
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
2005 Standout
Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O 2 -Regulated Prolyl Hydroxylation
2001 StandoutScienceNobel
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
2001 StandoutScienceNobel
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity
2018 StandoutScienceNobel
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models
2016 StandoutNatureNobel
Activation of the HIF pathway in cancer
2001
Epidermal Growth Factor and Hypoxia-induced Expression of CXC Chemokine Receptor 4 on Non-small Cell Lung Cancer Cells Is Regulated by the Phosphatidylinositol 3-Kinase/PTEN/AKT/Mammalian Target of Rapamycin Signaling Pathway and Activation of Hypoxia Inducible Factor-1α
2005
Hypoxia-Inducible Factors in Physiology and Medicine
2012 StandoutNobel
Hypoxia — a key regulatory factor in tumour growth
2002 Standout
MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas
1999
Expression, Assay, and Structure of the Extracellular Domain of Murine Carbonic Anhydrase XIV
2004
Recombinant Adenovirus Expressing Von Hippel-Lindau-Mediated Cell Cycle Arrest Is Associated with the Induction of Cyclin-Dependent Kinase Inhibitor p27Kip1
1998
Transcriptional Response to Hypoxia in Human Tumors
2001
SEC14L2 enables pan-genotype HCV replication in cell culture
2015 StandoutNatureNobel
C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation
2001 StandoutNobel
pVHL Acts as an Adaptor to Promote the Inhibitory Phosphorylation of the NF-κB Agonist Card9 by CK2
2007 StandoutNobel
Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL
2002 StandoutNatureNobel
The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity
1999
The von Hippel–Lindau tumor suppressor protein: new insights into oxygen sensing and cancer
2003 StandoutNobel
The von Hippel–Lindau Tumor Suppressor Gene
2001 StandoutNobel
Von Hippel‐Lindau gene alterations in sporadic benign and malignant pheochromocytomas
2003
von Hippel-Lindau Protein Induces Hypoxia-regulated Arrest of Tyrosine Hydroxylase Transcript Elongation in Pheochromocytoma Cells
1999
Molecular basis of the VHL hereditary cancer syndrome
2002 StandoutNobel
Regulation of tumor pH and the role of carbonic anhydrase 9
2007
Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function
2000
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
2012 StandoutNatureNobel
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
1999 StandoutNatureNobel
Ran-mediated Nuclear Export of the von Hippel-Lindau Tumor Suppressor Protein Occurs Independently of Its Assembly with Cullin-2
2000
Role of Exon 2-encoded β-Domain of the von Hippel-Lindau Tumor Suppressor Protein
2001
Yeast RNA Polymerase II at 5 Å Resolution
1999 StandoutNobel
von Hippel-Lindau Disease
1997 StandoutNobel
The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis
2000
Mutations of the VHL gene in sporadic renal cell carcinoma: Definition of a risk factor for VHL patients to develop an RCC
1999
Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling
2000 StandoutNobel
Expression of cell surface transmembrane carbonic anhydrase genes CA9 and CA12 in the human eye: overexpression of CA12 (CAXII) in glaucoma
2003
The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families
1998 StandoutNobel
HIF hydroxylation and the mammalian oxygen-sensing pathway
2003 StandoutNobel
Tracheal development and the von Hippel–Lindau tumor suppressor homolog in Drosophila
2000
A role for hypoxia and hypoxia-inducible transcription factors in tumor physiology
2002
Expression of the Hypoxia-Inducible and Tumor-Associated Carbonic Anhydrases in Ductal Carcinoma in Situ of the Breast
2001 StandoutNobel
Inhibition of Insulin-like Growth Factor-I-mediated Cell Signaling by the von Hippel-Lindau Gene Product in Renal Cancer
2000
Endoplasmic reticulum/cytosolic localization of von Hippel-Lindau gene products is mediated by a 64-amino acid region
2001
The natural history of cervical HPV infection: unresolved issues
2006
Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL
2002
Hypoxia activates the capacity of tumor‐associated carbonic anhydrase IX to acidify extracellular pH
2004
A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
2003 Standout
Tumour suppression by the human von Hippel-Lindau gene product
1995 StandoutNobel
VHL and Kidney Cancer
2003 StandoutNobel
Formation of the VHL–Elongin BC Tumor Suppressor Complex Is Mediated by the Chaperonin TRiC
1999
Selection of Mutant CHO Cells with Constitutive Activation of the HIF System and Inactivation of the von Hippel-Lindau Tumor Suppressor
2001 StandoutNobel
Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene
1998
Oxygen Sensing, Homeostasis, and Disease
2011 StandoutNobel
Identification of Elongin C Sequences Required for Interaction with the von Hippel-Lindau Tumor Suppressor Protein
1997
Cancer-related inflammation
2008 StandoutNature
Solitary retinal capillary hemangioma: Lack of genetic evidence for von Hippel-Lindau disease
2002
Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth
2003
Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1
2011 StandoutNobel
Expression of Hypoxia-Inducible Cell-Surface Transmembrane Carbonic Anhydrases in Human Cancer
2001
Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system
2001
HIF activation identifies early lesions in VHL kidneys
2002 StandoutNobel
Carbonic Anhydrase Inhibitors: Synthesis of Sulfonamides Incorporating 2, 4, 6–Trisubstituted-Pyridinium-Ethylcarboxamido Moieties Possessing Membrane-Impermeability and in Vivo Selectivity for the Membrane-Bound (CA IV) Versus the Cytosolic (CA I and CA II) Isozymes
2000
Software and database for the analysis of mutations in the VHL gene
1998
Mitochondria, calcium, and tumor suppressor Fus1: At the crossroad of cancer, inflammation, and autoimmunity
2015
The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer
2004 StandoutNobel
Playing Tag with HIF: The VHL Story
2002
Transcription-Dependent Nuclear-Cytoplasmic Trafficking Is Required for the Function of the von Hippel-Lindau Tumor Suppressor Protein
1999
Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer.
1995
Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex
2000
VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.
2000
Role of transforming growth factor-α in von Hippel– Lindau (VHL) −/− clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis
2001
Transcription Elongation and Human Disease
1999
Oxygen-Dependent Ubiquitination and Degradation of Hypoxia-Inducible Factor Requires Nuclear-Cytoplasmic Trafficking of the von Hippel-Lindau Tumor Suppressor Protein
2002
Hypoxia-inducible factor 1α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations
2000 StandoutNobel
Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C
1995 StandoutScienceNobel
Rbx1, a Component of the VHL Tumor Suppressor Complex and SCF Ubiquitin Ligase
1999 StandoutScienceNobel
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
HIF hydroxylation and the mammalian oxygen-sensing pathway
2003 StandoutNobel
Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor
2002 StandoutNobel
Analysis of the B‐cell repertoire against antigens expressed by human neoplasms
2002
The von Hippel-Lindau tumor suppressor targets to mitochondria.
2000
The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins
1997
Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene.
2003
The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion.
2001
Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations.
1995
The von Hippel-Lindau Tumor Suppressor Gene
2020
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
1996 Standout
Studying interactions of four proteins in the yeast two-hybrid system: Structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein
1999
The von Hippel–Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal
1998
VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells.
2002
Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice
1997
pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner
2016 StandoutScienceNobel
Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function
1999 StandoutScienceNobel
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
1996 StandoutNobel
A second major native von Hippel–Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor
1998
von Hippel-Lindau Protein-Mediated Repression of Tumor Necrosis Factor Alpha Translation Revealed through Use of cDNA Arrays
2003
Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling
2002 StandoutScienceNobel
Regulation of the Chemokine Receptor CXCR4 by Hypoxia
2003
Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells
2001
Carbonic Anhydrase Inhibitors: Synthesis of Membrane-Impermeant Low Molecular Weight Sulfonamides Possessing in Vivo Selectivity for the Membrane-Bound versus Cytosolic Isozymes
1999
pVHL Modification by NEDD8 Is Required for Fibronectin Matrix Assembly and Suppression of Tumor Development
2004 StandoutNobel
Tocopherol-Associated Protein Suppresses Prostate Cancer Cell Growth by Inhibition of the Phosphoinositide 3-Kinase Pathway
2005
Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma
2001 StandoutNobel
Review Article
2004
Tumor‐associated Carbonic Anhydrases and Their Clinical Significance
2006
Hypoxia-inducible expression of tumor-associated carbonic anhydrases.
2000 StandoutNobel
Factors regulating the transcriptional elongation activity of RNA polymerase II
1998
The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells
1999 StandoutNobel
Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2
1998 StandoutNobel
Structural Basis of Transcription: RNA Polymerase II at 2.8 Ångstrom Resolution
2001 StandoutScienceNobel
THE UBIQUITIN SYSTEM
1998 StandoutNobel
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Role ofVHLGene Mutation in Human Cancer
2004 StandoutNobel
Diverse Effects of Mutations in Exon II of the von Hippel-Lindau (VHL) Tumor Suppressor Gene on the Interaction of pVHL with the Cytosolic Chaperonin and pVHL-Dependent Ubiquitin Ligase Activity
2002 StandoutNobel
De novo design of protein logic gates
2020 StandoutScienceNobel
The Molecular Basis of Von Hippel-Lindau Disease
1997 StandoutNobel
Multiple Binding Modes of Inhibitors to Carbonic Anhydrases: How to Design Specific Drugs Targeting 15 Different Isoforms?
2012 Standout
Works of Igor Kuzmin being referenced
Epigenetic inactivation of RASSF1A in head and neck cancer.
2003
Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent
1998
Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells
2001
Von Hippel-Lindau disease: identification of deletion mutations by pulsed-field gel electrophoresis
1993
Isolation and characterization of the full-length 3′ untranslated region of the human von Hippel-Lindau tumor suppressor gene
1996
Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma
1996
The von Hippel-Lindau Tumor Suppressor Stabilizes Novel Plant Homeodomain Protein Jade-1
2002
Protective Function of von Hippel-Lindau Protein against Impaired Protein Processing in Renal Carcinoma Cells
1999
The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells.
2002
Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes
1998
Identification of the promoter of the human von Hippel-Lindau disease tumor suppressor gene.
1995